In the current study, we designed and selected a lipid-polymer hybrid nanoformulation from a series of various test nanoparticles capable of carrying siRNA to knockdown mutant p53 in a mouse osteosarcoma cell line. The gene discussed is TP53; the disease is osteosarcoma.